Blackhawk Plastic Surgery and other medspa operators are reporting a surge in body-contouring and skin-quality treatments among patients undergoing GLP-1 receptor agonist therapy (semaglutide, tirzepatide). The phenomenon reflects a predictable clinical pathway: rapid weight loss via GLP-1 creates loose skin, reduced skin elasticity, and patient demand for non-surgical tightening and texture improvement.
Treatments capturing this demand include RF microneedling (Morpheus8, XERF), monopolar RF, laser resurfacing, and injectables targeting skin quality (Profhilo, Radiesse, Juvéderm). The GLP-1 boom is creating a new patient cohort with both the motivation and disposable income to pursue aesthetic refinement—a tailwind for high-margin medspa services.